Positive benefits of theophylline in a randomized, double‐blind, parallel‐group, placebo‐controlled study of low‐dose, slow‐release theophylline in the treatment of COPD for 1 year
Positive benefits of theophylline in a randomized, double‐blind, parallel‐group, placebo‐controlled study of low‐dose, slow‐release theophylline in the treatment of COPD for 1 year
复制标题
DOI：
10.1111/j.1440-1843.2006.00897.x
复制
发表时间：
2006-09
期刊：
影响因子：
6.9
通讯作者：
Yumin Zhou;Xiao-ping Wang;Xiangyi Zeng;R. Qiu;Jun-fen Xie;Sheng-ming Liu;Jingping Zheng;N. Zhong;P. Ran
中科院分区：
文献类型：
--
作者：
Yumin Zhou;Xiao-ping Wang;Xiangyi Zeng;R. Qiu;Jun-fen Xie;Sheng-ming Liu;Jingping Zheng;N. Zhong;P. Ran
目的和背景：越来越多的证据表明，低剂量茶碱具有抗炎益处，并且在COPD治疗中是安全的。本研究旨在评价低剂量、缓释口服茶碱治疗COPD患者1年的疗效和安全性。
Objective and background: Increasing evidence suggests that low‐dose theophylline has anti‐inflammatory benefits and is safe in the treatment of COPD. This study aims to evaluate the efficacy and safety of low‐dose, slow‐release oral theophylline administered over a 1‐year period in patients with COPD.